Surge in alcohol-related disease during pandemic reveals unmet need for treatment

Alcohol-related deaths have climbed steadily over the past two decades, and with the onset of the COVID-19 pandemic, alcohol-associated disease and mortality rates have continued to soar.“It is clear that there has been an increase in hospitalizations for alcohol-associated hepatitis, at least at large tertiary centers,” Douglas Simonetto, MD, associate professor of medicine and director…

Alcohol-use disorder: Unmasked or exacerbated by the pandemic?

The COVID-19 pandemic stripped away layers of sugarcoating in our society — it exposed weak points across aspects of American life, stretched resources in public health and highlighted a deficit in recognition and access to mental health care and addiction medicine.Alcohol use is part of American culture. Alcohol is prominent in celebration as well as…

Restrictive diets offer greater symptom reduction vs. medical treatment in IBS patients

SAN DIEGO — Two restrictive diets were superior in reducing symptoms compared with optimized medical treatment alone in patients with irritable bowel syndrome, according to results presented at Digestive Disease Week 2022.“There are several different treatment options that are effective in alleviating symptoms of IBS, and dietary treatment indeed can be encouraged as a first-line…

FDA approves Opdivo-based combinations for esophageal squamous cell carcinoma

The FDA approved nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as first-line treatments for adults with unresectable advanced or metastatic esophageal squamous cell carcinoma.The agency based the approvals of the nivolumab (Opdivo, Bristol Myers Squibb) regimens on results of the randomized phase 3 CheckMate -648 trial, which investigated the anti-PD-1 antibody in…

Vedolizumab, ustekinumab best anti-TNF for infection risk in older adult IBD

SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age.“It used to be thought that IBD becomes a milder disease with age and, therefore, there never was a tremendous investment in better understanding…

Biologics linked to lower dementia rate in older patients with IBD

SAN DIEGO — Older patients with inflammatory bowel disease who were treated with biologics exhibited a lower incidence of dementia compared with those never treated with biologics, according to data presented at Digestive Disease Week 2022.“When we looked at a national database, what we found was an increased rate of dementia among IBD patients,” Ahmed…